目的：分析小剂量重组人干扰素α-1b治疗流行性腮腺炎的临床疗效。方法方便选取2015年4—10月期间收治的60例流行性腮腺炎患者，排除已经存在并发症的流行性腮腺炎患者。将所有患者随机分为两组，各30例，对照组采用利巴韦林注射液治疗，观察组在对照组治疗基础上加用重组人干扰素α-1b治疗，分析比较两组治疗有效率、并发症发生率及治疗情况。结果观察组治疗有效率为100.00%，显著高于对照组76.67%，P<0.05，差异有统计学意义；观察组患者退热时间及腮腺消肿时间均低于对照组，P<0.05，差异有统计学意义；观察组患者并发症发生率为3.33%，明显低于对照组30.00%，P<0.05，差异有统计学意义。结论小剂量重组人干扰素α-1b在治疗流行性腮腺炎中效果显著，可有效阻止病毒的扩散，在短时间内使患者临床症状得到缓解，治疗安全性高，在临床应用中值得推广使用。%Objective To analyze the clinical curative effect of small dose of recombinant human interferon alpha -1b treat-ment for mumps. Methods Convenient selection rrom April 2015—October 2015 treated 60 cases of mumps were excluded, there has been complications of mumps patients. All patients were randomly divided into two groups, each of 30 cases, con-trol group treated by Ribavirin Injection in the observation group, the control group based on the use of recombinant human interferon alpha -1b therapy, compared two groups of treatment efficiency, complications and treatment. Results The effec-tive rate of the observation group was 100%, significantly higher than the control group 76.67%, P< 0.05 significant differ-ence; the patients in the observation group were pyretolysis time and time of parotid gland swelling compared with the con-trol group, P<0.05 significant difference;the complication rate of observation group was 3.33%, significantly lower than the control group 30%, P< 0.05 respectively. Conclusion Low dose Recombinant human interferon in the treatment of mumps in effect significantly, can effectively prevent the virus diffusion. In a short period of time to clinical symptoms alleviated, the safety of treatment. In clinical application is worthy to be popularized.
展开▼
